Streetbeat News

Products Services

LIXT

Lixte Biotechnology has been granted a European patent for 'Oxabicycloheptane Prodrugs For Use In Treating Cancer'. This patent could enhance the company's intellectual property portfolio and potentially open new markets in Europe.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 5:11 pm

NIO

XPEV

Chinese EV stocks Nio, XPeng, and Li Auto saw significant attention on Monday due to strong May delivery numbers. Despite robust sales growth, shares of all three companies traded lower, likely due to concerns over price wars and weakening demand.

Portfolio Pulse from Anusuya Lahiri

June 03, 2024 | 5:09 pm

ETHUSD

GBTC

Bernstein research suggests that the SEC's approval of spot Ethereum ETFs was not politically influenced, despite President Biden's recent veto of a bill aimed at overturning SAB 121. Analysts argue the decision was pragmatic to avoid legal conflicts, especially after Grayscale's legal victory over the SEC.

Portfolio Pulse from Murtuza Merchant

June 03, 2024 | 5:09 pm

WKEY

WISeKey's subsidiary WISe.ART has partnered with the Sustainable Fashion Innovation Society to host a Phygital Sustainability Expo in Rome. This collaboration aims to promote sustainability in the fashion industry through a blend of physical and digital experiences.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 5:07 pm

AFMD

Affimed N.V. (NASDAQ:AFMD) shares surged after the company announced promising follow-up data from its AFM24-102 study in non-small cell lung cancer (NSCLC). The study showed significant efficacy in heavily pretreated patients, leading to a positive market reaction and a reiterated Buy rating from HC Wainwright & Co. with a $10 price target.

Portfolio Pulse from Erica Kollmann

June 03, 2024 | 4:58 pm

AFMD

Affimed shares are trading higher following the release of promising follow-up data from the EGFRwt cohort and initial clinical efficacy data from the EGFRmut cohort in the ongoing AFM24-102 study for NSCLC.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 4:56 pm

BMY

Bristol Myers Squibb (NYSE:BMY) announced positive results from multiple studies, including the Phase 3 KRYSTAL-12 study for Krazati in NSCLC and updated analyses from CheckMate studies for Opdivo and Breyanzi. These results have led to a 1.75% increase in BMY stock price.

Portfolio Pulse from Vandana Singh

June 03, 2024 | 4:51 pm

OSTX

OS Therapies announced a positive clinical update for its Phase 2b trial of OST-HER2 (OST31-154) in patients with resected, recurrent osteosarcoma. The trial showed a 1-year Event Free Survival (EFS) of 32.5% compared to 20% for the comparator, and an interim 1-year and 18-month Overall Survival (OS) of 90.4%. No severe treatment-related adverse events were reported. The trial is fully enrolled with 41 patients, and primary endpoint data will be released in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 4:46 pm

AAPL

AMD

EPI

EWW

GME

NVDA

QQQ

SPY

USO

India's stock market hits a lifetime high on exit polls predicting a landslide victory for Modi's BJP, while Mexico's peso and stocks fall on election results. AI advancements are announced by NVIDIA and AMD. Positive money flows are seen in major tech stocks and ETFs, while oil prices fall due to OPEC+ production changes.

Portfolio Pulse from The Arora Report

June 03, 2024 | 4:44 pm

PGEN

Precigen shares are trading higher following positive study data for PRGN-2012 for recurrent respiratory papillomatosis patients. Stifel has maintained a Buy rating on the stock and raised its price target from $7 to $10.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 4:39 pm